Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HyBryte vs Valchlor in CTCL
NCT06149247Phase 2Completed
- Sponsor
- Soligenix
- Start
- Dec 2023
- Primary completion
- May 2024
- Modality
- Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of hypericin in cutaneous T-cell lymphoma (CTCL), sponsored by Soligenix. Started Dec 2023; status: completed.
02
Drugs
hypericin
03
Conditions
cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on NCT06149247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06149247.